Elinzanetant (BAY3427080) + Rosuvastatin
Phase 1Completed 0 watching 0 views this week๐ค Quiet
30
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
Conditions
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
Trial Timeline
May 26, 2021 โ Sep 29, 2021
NCT ID
NCT04889287About Elinzanetant (BAY3427080) + Rosuvastatin
Elinzanetant (BAY3427080) + Rosuvastatin is a phase 1 stage product being developed by Bayer for Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men. The current trial status is completed. This product is registered under clinical trial identifier NCT04889287. Target conditions include Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04889287 | Phase 1 | Completed |
Competing Products
20 competing products in Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men